Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)

Table 2 Treatment response of H101 group and control group

	Overall	H101(none + Anti-HBV Therapy,P = 0.162)	Control	P value
				0.010
CR	38(21.7 %)	25 (28.7 %)(16 + 9)	13(14.8 %)	0.017
PR	47(26.9 %)	28(32.2 %)(21 + 7)	19(21.6 %)	0.172
SD	57(32.6 %)	23(26.4 %)(14 + 9)	34(38.6 %)	0.107
PD	33(18.9 %)	11(12.6 %)(4 + 7)	22(25 %)	0.011

All patients enrolled in H101 group were screened to sort out cases with anti-HBV therapy or without anti-HBV therapy.
None: Patients treated by H101 without anti-HBV therapy.
Anti-HBV Therapy: Patients treated by H101 with anti-HBV therapy session.

ISSN: 1471-2407